deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02098538

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Sponsor: Bayer

Conditions Adenoid Cystic Carcinoma
Interventions Regorafenib
Updated 16 times since 2017 Last updated: Sep 8, 2025 Started: Mar 31, 2014 Primary completion: Nov 7, 2024 Completion: Nov 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02098538, this PHASE2 trial focuses on Adenoid Cystic Carcinoma and remains completed. Sponsored by Bayer, it has been updated 16 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~May 2023 · 12 months · monthly snapshot~May 2023 – ~May 2024 · 12 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE2

  3. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  3. May 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  4. May 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  6. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. May 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  9. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations